next generation colorectal cancer screening

Our company

CRCbioscreen was founded in 2021 as a spin off company from the Netherlands Cancer Institute. The company holds an exclusive license on the intellectual property of NKI's Translational Gastrointestinal Oncology group regarding a stool based screening test directed against a combination of proteins has the potential to increase sensitivity for high risk precursor lesions of colorectal cancer